SavedAdd your journal

Journals / Marmara Medical Journal / 2026 / Volume: 23 Issue: 3

-

BEYİN KİTLELERİNDE NEOPLASTİK / NEOPLASTİK OLMAYAN VE YÜKSEK EVRE / DÜŞÜK EVRE AYRIMINDA MR SPEKTROSKOPİNİN YERİ

Ozan Karatağ
Gülden Yenice Karatağ
Ender Uysal
S. Can
Mehmet Ertürk
Muzaffer Başak
Pages
—
Publication Date
2015-04-28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗

Abstract

-

Özet

Amaç: Bu çalışmanın amacı serebral lezyonların ayırıcı tanısında Manyetik Rezonans Spektroskopinin etkinliğini araştırmaktır. Yöntem: Serebral lezyonu olan 46 olgu Manyetik Rezonans Spektroskopi ile incelendi. Kolin, kreatin, Nasetil aspartat ve lipid-laktat pikleri değerlendirildi. Kırk altı olgunun 40'ına stereotaktik biopsi ya da operasyon uygulandı. Histopatolojik sonuçlar ile Manyetik Rezonans Spektroskopi sonuçları karşılaştırıldı. Bulgular: Lezyonların neoplastik/neoplastik olmayan ayrımında Kolin/N-asetil aspartat en yüksek duyarlılığa sahipti (%87.2) ve Kolin/Kreatin, Kolin/N-asetil aspartat, Kolin+Kreatin/N-asetil aspartat oranlarının özgüllük değerleri %100 olarak hesaplandı. Düşük/yüksek evre ayrımında Kolin/Kreatin en yüksek duyarlılığa sahipti (%95.7) ve Kolin/N-asetil aspartat, Kolin+Kreatin/N-asetil aspartat, lipid-laktat oranlarının özgüllüğü %100 olarak hesaplandı. Sonuç olarak Kolin/Kreatin oranının 2.2'den yüksek olması ve eşlik eden lipid-laktat pikinin neoplastik lezyonların düşük/yüksek evre ayrımında %100 (%82.2-100) duyarlılık ve %100 (%71.7-100) özgüllüğe sahip olduğu görüldü. Sonuç: Yüksek Kolin ve düşük N-asetil aspartat piklerinin lezyonların neoplastik/neoplastik olmayan ayrımında etkili olduğu görüldü. Neoplastik lezyonların yüksek/düşük evre ayrımında ise 2.2'den yüksek Kolin/Kreatin oranı ve eşlik eden lipid-laktat pikinin değerli bilgiler verdiği sonucuna varıldı. Anahtar Kelimeler: Beyin neoplazmları, Manyetik rezonans görüntüleme, Manyetik rezonans spektroskopi, Stereotaktik biyopsi

🔖

Cite This Article

Karatağ, O., Karatağ, G. Y., Uysal, E., Can, S., Ertürk, M., Başak, M. (2015). -. Marmara Medical Journal, Volume: 23 Issue: 3. https://ajindex.com/articles/1287006

References (171)

  1. Dowling C, Bollen AW, Noworolski SM, et al.
  2. Preoperative proton MR spectroscopic imaging of brain
  3. tumors: correlation with histopathologic analysis of
  4. resection specimens specimens. AJNR Am J
  5. Neuroradiol 2001; 22: 604–612.
  6. Hourani R, Brant LJ, Rizk T, Weingart JD, Barker PB,
  7. Horská A. Can proton MR spectroscopic and perfusion
  8. imaging differentiate between neoplastic and
  9. nonneoplastic brain lesions in adults? AJNR Am J
  10. Neuroradiol 2008; 29:366-372.
  11. Stadlbauer A, Gruber S, Nimsky C, et al. Preoperative
  12. grading of gliomas by using metabolite quantification
  13. with high-spatial-resolution proton MR spectroscopic
  14. imaging. Radiology 2006; 238:958-969.
  15. Bulakbasi N, Kocaoglu M, Ors F, Tayfun C, Ucoz T.
  16. Combination of single-voxel proton MR spectroscopy
  17. and apparent diffusion coefficient calculation in the
  18. evaluation of common brain tumors. AJNR Am J
  19. Neuroradiol 2003; 24:225-233.
  20. Bernstein M, Parrent AG. Complications of CT-guided
  21. stereotactic biopsy of intra-axial brain lesions. J
  22. Neurosurg 1994; 81:165–168.
  23. Field M, Witham TF, Flickinger JC, Kondziolka D,
  24. Lunsford LD. Comprehensive assessment of
  25. hemorrhage risks and outcomes after stereotactic brain
  26. biopsy. J Neurosurg 2001; 94:545–551.
  27. Kreth FW, Muacevic A, Medele R, Bise K, Meyer T,
  28. Reulen HJ. The risk of haemorrhage after image guided
  29. stereotactic biopsy of intra-axial brain tumours: a
  30. prospective study. Acta Neurochir (Wien) 2001; 143:
  31. Sawin PD, Hitchon PW, Follett KA, Torner JC.
  32. Computed imaging-assisted stereotactic brain biopsy: a
  33. risk analysis of 225 consecutive cases. Surg Neurol; 49:640–649.
  34. Yu X, Liu Z, Tian Z, Li S, Huang H, et al. Stereotactic
  35. biopsy for intracranial space-occupying lesions: clinical
  36. analysis of 550 cases. Stereotact Funct Neurosurg 2000;:103–108.
  37. Law M, Yang S, Wang H, et al. Glioma grading:
  38. sensitivity, specificity, and predictive values of
  39. perfusion MR imaging and proton MR spectroscopic
  40. imaging compared with conventional MR imaging.
  41. AJNR Am J Neuroradiol 2003; 24:1989-1998.
  42. Al-Okaili RN, Krejza J, Woo JH, Wolf RL, O'Rourke
  43. DM, Judy KD, et al. Intraaxial brain masses: MR
  44. imagingbased diagnostic strategy—initial experience.
  45. Radiology 2007; 243:539–550.
  46. García-Gómez JM, Luts J, Julià-Sapé M, et al.
  47. Multiproject-multicenter evaluation of automatic brain
  48. tumor classification by magnetic resonance
  49. spectroscopy. MAGMA 2009; 22:5-18.
  50. Lin AP, Ross BD. Short-echo time proton MR
  51. spectroscopy in the presence of gadolinium. J Comput
  52. Assist Tomogr 2001; 25:705-712.
  53. Murphy PS, Dzik-Jurasz AS, Leach MO, Rowland IJ.
  54. The effect of Gd-DTPA on T(1)-weighted choline signal
  55. in human brain tumours. Magn Reson Imaging 2002;:127-130.
  56. Smith JK, Kwock L, Castillo M. Effects of contrast
  57. material on single-volume proton MR spectroscopy.
  58. AJNR Am J Neuroradiol 2000; 21:1084-1089.
  59. Spampinato MV, Smith JK, Kwock L, et al. Cerebral
  60. blood volume measurements and proton MR
  61. spectroscopy in grading of oligodendroglial tumors. AJR
  62. Am J Roentgenol 2007; 188:204-212.
  63. Bruhn H, Frahm J, Gyngell ML, et al. Noninvasive
  64. differentiation of tumors with use of localized H-1 MR
  65. spectroscopy in vivo: initial experience in patients with
  66. cerebral tumors. Radiology 1989; 172: 541–548.
  67. Castillo M, Kwock L, Mukherji SK. Clinical
  68. applications of MR spectroscopy. AJNR Am J
  69. Neuroradiol 1996; 17:1–15.
  70. Krouwer HG, Kim TA, Rand SD, et al. Single-voxel
  71. proton MR spectroscopy of nonneoplastic brain lesions
  72. suggestive of a neoplasm. AJNR Am J Neuroradiol; 19:1695–1703.
  73. Poptani H, Gupta RK, Roy R, Pandey R, Jain VK,
  74. Chhabra DK. Characterization of intracranial mass
  75. lesions with in vivo proton MR spectroscopy. AJNR Am
  76. J Neuroradiol 1995; 16:1593–1603.
  77. Segebarth CM, Baleriaux DF, Luyten PR, den Hollander
  78. JA. Detection of metabolic heterogeneity of human
  79. intracranial tumors in vivo by H-1 NMR spectroscopic
  80. imaging. Magn Reson Med 1990; 13:62–76.
  81. Rand SD, Prost R, Haughton V, et al. Accuracy of
  82. single-voxel proton MR spectroscopy in distinguishing
  83. neoplastic from nonneoplastic brain lesions. AJNR Am J
  84. Neuroradiol 1997; 18:1695–1704.
  85. Demaerel P, Johannik K, van Hecke P, et al. Localized
  86. H NMR spectroscopy in fifty cases of newly diagnosed
  87. intracranial tumors. J Comput Assist Tomogr 1991;:67–76.
  88. Herholz K, Heindel W, Luyten PR, et al. In vivo
  89. imaging of glucoseconsumption and lactate
  90. concentration in human gliomas. Ann Neurol 1992;:319–327.
  91. Ott D, Hennig J, Ernst T. Human brain tumors:
  92. assessment with in vivo proton MR spectroscopy.
  93. Radiology 1993; 186:745–752.
  94. Shimizu H, Kumabe T, Tominaga T, et al. Noninvasive
  95. evaluation of malignancy of brain tumors with proton
  96. MR spectroscopy. AJNR Am J Neuroradiol 1996;:737-747.
  97. Kugel H, Heindel W, Ernestus R-I, Bunke J, du Mensil
  98. R, Friedmann G. Human brain tumors: spectral patterns
  99. detected with localized H-1 MR spectroscopy.
  100. Radiology 1992; 183:701–709.
  101. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain
  102. tumor metabolites with proton MR spectroscopic
  103. imaging: clinical relevance. Radiology 1992; 185:675-
  104. Marmara Medical Journal 2010;23(3); 326-338
  105. Ozan Karatağ, et al.
  106. Can magnetic resonance spectroscopy adequately differentiate neoplastic from non-neoplastic and low-grade from highgrade
  107. lesions in brain masses?
  108. Kinoshita Y, Kajiwara H, Yokota A, Koga Y. Proton
  109. magnetic resonance spectroscopy of brain tumors: an in
  110. vitro study. Neurosurgery 1994; 35:606–614.
  111. Tien RD, Lai PH, Smith JS, Lazeyras F. Single-voxel
  112. proton brain spectroscopy exam (PROBE/SV) in
  113. patients with primary brain tumors. AJR Am J
  114. Roentgenol 1996; 167:201-209.
  115. Meyerand ME, Pipas JM, Mamourian A, Tosteson TD,
  116. Dunn JF. Classification of biopsy-confirmed brain
  117. tumors using single-voxel MR spectroscopy. AJNR Am
  118. J Neuroradiol 1999; 20:117–123.
  119. Moller-Hartmann W, Herminghaus S, Krings T, et al.
  120. Clinical application of proton magnetic resonance
  121. spectroscopy in the diagnosis of intracranial mass
  122. lesions. Neuroradiology 2002; 44:371–381.
  123. Kimura T, Sako K, Gotoh T, Tanaka K, Tanaka T. In
  124. vivo singlevoxel proton MR spectroscopy in brain
  125. lesions with ring-like enhancement. NMR Biomed 2001;:339–349.
  126. Poptani H, Gupta RK, Jain VK, Roy R, Pandey R.
  127. Cystic intracranial mass lesions: possible role of in vivo
  128. MR spectroscopy in its differential diagnosis. Magn
  129. Reson Imaging 1995; 13:1019-1029.
  130. Luyten PR, Marien AJ, Heindel W,, et al. Metabolic
  131. imaging of patients with intracranial tumors: 1H MR
  132. spectroscopic imaging and PET. Radiology 1990;:791–799.
  133. Martin AJ, Liu H, Hall WA, Truwit CL. Preliminary
  134. assessment of turbo spectroscopic imaging for targeting
  135. in brain biopsy. AJNR Am J Neuroradiol 2001; 22:959-
  136. Bizzi A, Movsas B, Tedeschi G, et al. Response of nonHodgkin
  137. lymphoma to radiation therapy: early and longterm
  138. assessment with H-1 MR spectroscopic imaging.
  139. Radiology 1995; 194:271-276.
  140. Law M, Cha S, Knopp EA, Johnson G, Arnett J, Litt
  141. AW. High-grade gliomas and solitary metastases:
  142. differentiation by using perfusion and proton
  143. spectroscopic MR imaging. Radiology 2002; 222:715-
  144. Bendszus M, Warmuth-Metz M, Klein R. MR
  145. spectroscopy in gliomatosis cerebri. Am J Neuroradiol; 21:375–380.
  146. Pyhtinen J. Proton MR spectroscopy in gliomatosis
  147. cerebri. Neuroradiology 2000; 42:612–615.
  148. Uysal E, Erturk M, Yildirim H, et al. Multivoxel
  149. magnetic resonance spectroscopy in gliomatosis cerebri.
  150. Acta Radiol 2005; 46:621-624.
  151. Garg M, Gupta RK, Husain M, et al. Brain abscesses:
  152. etiologic categorization with in vivo proton MR
  153. spectroscopy. Radiology 2004; 230:519-527.
  154. Kim DG, Choe WJ, Chang KH, et al. In vivo proton
  155. magnetic resonance spectroscopy of central
  156. neurocytomas. Neurosurgery 2000; 46:329-334.
  157. Lee DY, Chung CK, Hwang YS, et al.
  158. Dysembryoplastic neuroepithelial tumor: radiological
  159. findings (including PET, SPECT, and MRS) and
  160. surgical strategy. J Neurooncol 2000; 47:167–174.
  161. Sener RN. Neuro-Behcet's disease: diffusion MR
  162. imaging and proton MR spectroscopy. AJNR Am J
  163. Neuroradiol 2003; 24:1612-1614.
  164. Baysal T, Ozisik HI, Karlidag R, et al. Proton MRS in
  165. Behcet’s disease with and without neurological findings.
  166. Neuroradiol 2003; 45:860-864.
  167. Appenzeller S, Li LM, Costallat LT, Cendes F.
  168. Neurometabolic changes in normal white matter may
  169. predict appearance of hyperintense lesions in systemic
  170. lupus erythematosus. Lupus 2007; 16:963-971.
  171. Luyten PR, Marien AJ, Heindel W,, et al. Metabolic